現在地

松阪 諭(マツサカ サトシ; Matsusaka, Satoshi)

所属
医学医療系
職名
教授
職歴
2015-10 -- 2018-05がん研有明病院 消化器内科 がん研究所蛋白創製研究部兼任 医長
2013-10 -- 2015-09南カリフォルニア大学 腫瘍内科 ポスドクフェロー
2012-02 -- 2013-09がん研有明病院 消化器内科 医長
2006-04 -- 2012-01がん研有明病院 化学療法科 医員
2004-04 -- 2006-03山形大学 医学部医学科環境病態医学分野 助教
2002-04 -- 2003-03神戸大学 医学系研究科機能ゲノム学分野 COE研究員
2000-04 -- 2002-03宝塚市立病院 外科 医員
1994-04 -- 2000-03兵庫医科大学 第一外科 医員
その他の論文・記事
  • A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
    MD Berger; S Stintzing; V Heinemann; S Cao; D Yang; Sunak...
    Clin Cancer Res/24(4)/pp.784-793, 2018-2
  • Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; F Loupakis; D Yang; C Cremolini; M Schirripa; M...
    Clin Colorectal Cancer./17(3)/pp.e471-e488, 2018-9
  • Intelligent Image-Activated Cell Sorting
    N Nitta; T Sugimura; A Isozaki; H Mikami; K Hiraki; S Sak...
    Cell/175(1)/pp.266-276, 2018-9
  • Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.
    T Wakatsuki; S Stintzing; W Zhang; D Yang; M Azuma; Y Nin...
    Pharmacogenet Genomics/24(11)/pp.539-547, 2014
  • Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
    M Suenaga; Mizunuma N; S Matsusaka; E Shinozaki; M Ueno; ...
    Asia Pac J Clin Oncol/10(4)/pp.322-329, 2014
  • A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid.
    Matsusaka Satoshi; M Kozuka; Takagi H; H Ito; Minowa S; M...
    Cancer Lett/355(1)/pp.113-120, 2014
  • Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer
    Sebio A; A Gerger; S Matsusaka; D Yang; W Zhang; S Stremi...
    Pharmacogenet Genomics./25(1)/pp.30-37, 2015
  • Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer.
    Y Sunakawa; S Stremitzer; S Cao; W Zhang; D Yang; T Wakat...
    Ann Oncol./26(2)/pp.332-339, 2015
  • A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
    Ishihara S; S Matsusaka; K Kondo; H Horie; Uehara K; M Og...
    Radiat Oncol/10/pp.24-24, 2015
  • Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab.
    M Suenaga; N Mizunuma; E Shinozaki; S Matsusaka; M Ozaka;...
    Onco Targets Ther/8/pp.243-249, 2015
  • Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.
    S Stremitzer; W Zhang; D Yang; Y Ning; S Stintzing; A Seb...
    Cancer/121(11)/pp.1898-1905, 2015
  • Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. Pharmacogenomics J
    S Stremitzer; Y Sunakawa; W Zhang; D Yang; Y Ning; S Stin...
    Pharmacogenomics J/15(6)/pp.521-529, 2015
  • A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction
    S Suzuki; S Matsusaka; M Hirai; H Shibata; K Takagi; N Mi...
    Int J Oncol/47(1)/pp.97-105, 2015
  • Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases.
    Stremitzer S; W Zhang; Yang D; Y Ning; S Stintzing; Y Sun...
    Ann Oncol./26(8)/pp.1728-1733, 2015
  • Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
    M Suenaga; Fujimoto Y; S Matsusaka; E Shinozaki; T Akiyos...
    Onco Targets Ther/8/pp.1111-1118, 2015
  • Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
    M Suenaga; N Mizunuma; S Matsusaka; E Shinozaki; M Ozaka;...
    Drug Des Devel Ther/9/pp.3099-3108, 2015
  • Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
    Stintzing S; Zhang W; Heinemann V; Neureiter D; Kemmerlin...
    Mol Cancer Ther/14(10)/pp.2374-2381, 2015
  • Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.
    Y Ning; DL Hanna; W Zhang; A Mendez; D Yang; R El-Khoueir...
    Mol Cancer Ther/14(10)/pp.2401-2408, 2015
  • Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab.
    H Osumi; S Matsusaka; M Suenaga; E Shinozaki; N Mizunuma
    Onco Targets Ther./8/pp.2005-2013, 2015
  • A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial)
    Matsusaka Satoshi; Ishihara S; K Kondo; H Horie; K Uehara...
    Radiother Oncol/116(2)/pp.209-213, 2015
  • Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
    Y Sunakawa; S Stintzing; S Cao; V Heinemann; C Cremolini;...
    Ann Oncol./26(12)/pp.2450-2456, 2015
  • Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
    Matsusaka Satoshi
    Ann Oncol./26(12)/pp.2450-2456, 2015
  • Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
    H Osumi; E Shinozaki; M Suenaga; Y Kumekawa; M Ogura; M O...
    BMC Cancer/15/pp.760-760, 2015
  • Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
    H Osumi; E Shinozaki; M Osako; Y Kawazoe; M Oba; T Misaka...
    Mol Clin Oncol./3(5)/pp.1053-1057, 2015
  • Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients.
    Y Sato; S Matsusaka; M Suenaga; E Shinozaki; N. Mizunuma
    Onco Targets Ther./8/pp.3329-3336, 2015

(最終更新日: 2018-09-23)